- DKK13.54bn
- DKK11.39bn
- DKK6.24bn
Brief: Bavarian Nordic Secures Additional Government Contract For The Supply Of Smallpox/Mpox Vaccine
Brief: Bavarian Nordic Launches Final Tranche Of Buy-Back Program
Bavarian Nordic falls as high costs, lower vaccine sales hit Q1 results
Bavarian Nordic Q1 revenue falls as Public Preparedness unit sales decline
Brief: Bavarian Nordic Keeps 2026 Outlook Maintained
Bavarian Nordic rises 3% after guidance hike
Bavarian Nordic raises 2026 forecast on additional US vaccine contract (updated)
Denmark's Bavarian Nordic raises 2026 forecast
Brief: Bavarian Nordic Says Awarded Contract Options From The U.S. Government For Production And Supply Of Freeze-Dried Smallpox Vaccines
Brief: Reg-Bavarian Nordic Completes Share Buy-Back Program
Brief: Bavarian Nordic Gets Swissmedic Approval For Chikungunya Vaccine
Brief: Bavarian Nordic Launches Next Tranche Of Share Buy-Back Program
Brief: Bavarian Nordic FY Revenue At DKK 6,244 Million, In Line With Preliminary Number
Brief: Bavarian Nordic, Serum Institute Of India Expand Strategic Partnership
Brief: Paul Chaplin Steps Down As CEO Of Bavarian Nordic
Brief: Bavarian Nordic Gets USD 22.5 Mln Deal For Mpox, Smallpox Vaccine
Denmark's Bavarian Nordic prelim 2025 revenue beats on vaccine demand
Brief: Bavarian Nordic FY Revenue DKK 6,244 Million
Brief: Bavarian Nordic Completion Of Share Buy-Back Program